Robert Stanley, MD, PhD
We post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
Conditions I Treat
- Leukemia
- Acute lymphocytic leukemia (ALL)
- Acute myeloid leukemia (AML)
Get to Know Me
I am a medical oncologist and physician-scientist who cares for people with blood cancers, specifically those with acute and chronic leukemias.
My first encounter with patients and their caregivers is the most important. Understandably, patients often feel anxious and concerned about their diagnosis and what it means for their future. I make it a priority to listen to my patients, thoroughly answer their questions, and address their concerns. I review with them how their diagnosis and treatment will affect their lives and the lives of their caregivers.
I take the time to understand each patient’s goals and tailor their treatment options accordingly. My goal is to make sure my patients feel well-informed and supported throughout their cancer journey.
At present, I spend much of my time dedicated to basic and translational research with a particular interest in splicing and immunology in the context of myeloid blood cancers. My mission is to identify new targets and strategies to treat blood cancers to improve the lives of my patients.
I’m a leukemia specialist, which is a doctor with special training in diagnosing and treating leukemia (loo-KEE-mee-uh). This cancer starts in tissue that forms blood, such as bone marrow.
- Instructor
Conditions I Treat
- Leukemia
- Acute lymphocytic leukemia (ALL)
- Acute myeloid leukemia (AML)
- Acute promyelocytic leukemia (APL)
- Chronic lymphocytic leukemia (CLL)
- Chronic myeloid leukemia (CML)
- Myeloproliferative neoplasms (MPN)/Myeloproliferative disorders
- Myelodysplastic syndrome (MDS)
- Hairy cell leukemia (HCL)
- Systemic mastocytosis
- Blood, bone marrow, and hematologic cancers and conditions
Education
- MD, Albert Einstein College of Medicine
- PhD, Albert Einstein College of Medicine
Residencies
- Internal Medicine, NewYork Presbyterian/Weill Cornell Medical Center
Fellowships
- Medical Oncology, Memorial Sloan Kettering Cancer Center
Board Certifications
- Internal Medicine
- Medical Oncology
Awards and Honors
- Doris Duke Foundation Physician-Scientist Award (2023)
- Young Investigator Award, American Society of Clinical Oncology (2023)
- American Society of Hematology Research Training Award for Fellows (2022)
- MSK T32 Investigational Cancer Therapeutics Award (2021)
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
HMO, EPO PPO, POS, Transplant
In Network Coverage Type
PPO
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
PPO, HMO
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
Supplemental
In Network Coverage Type
PPO, POS, HMO
In Network Coverage Type
POS, EPO, HMO
In Network Coverage Type
State Government
In Network Coverage Type
State Government
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO, HMO
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
State Government
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO EPO
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
TBD
In Network Coverage Type
PPO, POS, EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
HMO
City Employee Health Plans (Gold and Gold Care)
In Network Coverage Type
Supplemental
In Network Coverage Type
PPO/OAP
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
HMO/EPO
In Network Coverage Type
PPO, EPO
In Network Coverage Type
State Government
In Network Coverage Type
PPO, POS, HMO
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO, POS
In Network Coverage Type
PPO, POS, HMO
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
Contact and Location
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
1) Cortés-López M*, Chamely P*, Hawkins AG*, Stanley RF*, Swett AD, Ganesan S, Mouhieddine TH, Dai X, Kluegel L, Chen C, Batta K, Furer N, Vedula RS, Beaulaurier J, Drong AW, Hickey S, Dusaj N, Mullokandov G, Stasiw AM, Su J, Chaligné R, Juul S, Harrington E, Knowles DA, Potenski CJ, Wiseman DH, Tanay A, Shlush L, Lindsley RC, Ghobrial IM, Taylor J, Abdel-Wahab O, Gaiti F, Landau DA. Single-cell multi-omics defines the cell-type-specific impact of splicing aberrations in human hematopoietic clonal outgrowths. Cell Stem Cell. 2023 Sep 7;30(9):1262-1281.e8. PubMed Central PMCID: PMC10528176. *Co-first/equal contributors
2) Stanley RF, Abdel-Wahab O. Dysregulation and therapeutic targeting of RNA splicing in cancer. Nat Cancer. 2022 May;3(5):536-546. PubMed Central PMCID: PMC9551392.
3) Stanley RF*, Piszczatowski RT*, Bartholdy B, Mitchell K, McKimpson WM, Narayanagari S, Walter D, Todorova TI, Hirsch C, Makishima H, Will B, McMahon C, Gritsman K, Maciejewski JP, Kitsis RN, Steidl U. A myeloid tumor suppressor role for NOL3. J Exp Med. 2017 Mar 6;214(3):753-771. PubMed Central PMCID: PMC5339683. *Co-first/equal contributors
4) Pandolfi A*, Stanley RF*, Yu Y, Bartholdy B, Pendurti G, Gritsman K, Boultwood J, Chernoff J, Verma A, Steidl U. PAK1 is a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome. Blood. 2015 Aug 27;126(9):1118-27. PubMed Central PMCID: PMC4551362. *Co-first/equal contributors
Visit PubMed for a full listing of Dr. Stanley’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Members of the MSK Community often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community. These activities outside of MSK further our mission, provide productive collaborations, and promote the practical application of scientific discoveries.
MSK requires doctors, faculty members, and leaders to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public. Not all disclosed interests and relationships present conflicts of interest. MSK reviews all disclosed interests and relationships to assess whether a conflict of interest exists and whether formal COI management is needed.
Robert Stanley discloses the following relationships and financial interests:
-
Codify Therapeutics, Inc.
Intellectual Property Rights
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2024 through disclosure submission in spring 2025). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].